Crossing the borders of innovationBasing clinical trials on sound mechanistic and scientific rationale. Combating Pan-Cancer with PrecisionSaving Lives of Patients Who Exhausted Treatment Options and Improving Clinical BenefitsCancer Patients are fighting for their lives...we will fight with themImagining a world without cancer. Apollomics is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies. Pipeline Science Events Our Vision To become a global leader in the development of novel medicines for cancer patients. Learn More Recent News January 7, 2021 APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia November 11, 2020 APOLLOMICS, INC. RECEIVES CHINA INVESTIGATIONAL NEW DRUG APPROVAL FOR APL-102 TO INITIATE A PHASE 1 STUDY More News
